Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

• Ngā kaituhi matua: Archana Jastorff (Author), Arangassery Rosemary Bastian (Author), Nynke Ligtenberg (Author), Vladislav Klyashtornyy (Author), Benoît Callendret (Author), Esther Heijnen (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

The Ad26.RSV.preF/RSV preF protein vaccine has previously demonstrated efficacyin protecting older adults against respiratory syncytial virus (RSV)-related lower respiratory tract disease in a phase 2b study. This study compared the immunogenicity of vaccine clinical trial material (CTM) representat...